Key result
Journal masthead and editorial board listing contains no clinical trial data.
Why the study?
Antiplatelet therapy is a mainstay in the pharmacological treatment of CAD, with several drug classes developed over recent decades resulting in a broad available armamentarium.
This review provides a comprehensive overview of the evolution and current state of antiplatelet therapy in the management of coronary artery disease.
No new trial data available; leaves open need for primary evidence on antiplatelet therapy in CAD.
Cardiovascular disease, particularly coronary artery disease (CAD), remains the leading cause of mortality and morbidity in industrialized countries. Platelet activation and aggregation at the site of endothelial injury play a key role in the processes ultimately resulting in thrombus formation with vessel occlusion and subsequent end-organ damage. Consequently, antiplatelet therapy has become a mainstay in the pharmacological treatment of CAD. Several drug classes have been developed over the last decades and a broad armamentarium of antiplatelet agents is currently available. This review portrays the evolution of antiplatelet therapy, and provides an overview on previous and current antiplatelet drugs and strategies.
No takes yet. Share an insight, caveat, or question.
Tscharre et al. (2022) studied Coronary Artery Disease. Antiplatelet Therapy was evaluated. This document is a journal masthead and editorial board listing, containing no clinical trial data or findings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: